Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell lung cancer. (Abstract LBA43)
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses in Italian study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non–small cell lung cancer previously treated with chemotherapy and crizotinib.
Omid Hamid, MD, of The Angeles Clinic and Research Institute, discusses survival data from this clinical trial on pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory melanoma. (Abstract 1107O) Follow him on Twitter: @omidhamidmd
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses interim findings on abemaciclib in postmenopausal women with HR+/HER2- breast cancer. (Abstract LBA13)
Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorectal cancer. (Abstract 453O)
